- Home
- ALT
ALT
Altimmune Inc.
as 01-21-2025 4:00pm EST
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 529.9M | IPO Year: | N/A |
| Target Price: | $19.71 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.28 - $14.84 | Next Earning Date: | 11-12-2024 |
| Revenue: | $52,000 | Revenue Growth: | -81.36% |
| Revenue Growth (this year): | -98.42% | Revenue Growth (next year): | N/A |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
GlobeNewswire
a month ago
Altimmune Added to Nasdaq Biotechnology Index
GlobeNewswire
2 months ago
Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders
GlobeNewswire
2 months ago
Altimmune to Participate at Two Upcoming Investor Conferences
GlobeNewswire
2 months ago
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Simply Wall St.
2 months ago
Altimmune Third Quarter 2024 Earnings: Beats Expectations
GlobeNewswire
2 months ago
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
2 months ago
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.